125 related articles for article (PubMed ID: 26835590)
1. Podoplanin serum and urine concentration in transitional bladder cancer.
Sankiewicz A; Guszcz T; Mena-Hortelano R; Zukowski K; Gorodkiewicz E
Cancer Biomark; 2016; 16(3):343-50. PubMed ID: 26835590
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic Efficiency of Serum and Urine Procathepsin B and Cathepsin B in Patients with Carcinoma of the Urinary Bladder.
Dusek P; Kotaska K; Vesely S; Prusa R; Babjuk M
Clin Lab; 2016 Sep; 62(9):1709-1715. PubMed ID: 28164592
[TBL] [Abstract][Full Text] [Related]
3. Serum and urine ferritin in patients with transitional cell carcinoma of the bladder.
Migliari R; Mela Q; Ruggiero V; Scarpa RM; Migliari M; Pitzus F; Usai E
Arch Ital Urol Nefrol Androl; 1991 Mar; 63(1):141-5. PubMed ID: 1830406
[TBL] [Abstract][Full Text] [Related]
4. Presence of CSE1L protein in urine of patients with urinary bladder urothelial carcinomas.
Tai CJ; Liao CF; Su TC; Shen KH; Chang CC; Lin SH; Yeh CM; Shen SC; Lee WR; Chiou JF; Lin CH; Chen YC; Shih HY; Yeh KT; Jiang MC
Int J Biol Markers; 2012 Oct; 27(3):e280-4. PubMed ID: 22653741
[TBL] [Abstract][Full Text] [Related]
5. Immunocytochemically demonstrated expression of epithelial membrane antigen and carcinoembryonic antigen by exfoliated urinary cells in patients with bladder cancer.
Tanaka K; Takashi M; Miyake K; Koshikawa T
Urol Int; 1994; 52(3):140-4. PubMed ID: 8203052
[TBL] [Abstract][Full Text] [Related]
6. Recovery of epidermal growth factor in voided urine of patients with bladder cancer.
Messing EM; Murphy-Brooks N
Urology; 1994 Oct; 44(4):502-6. PubMed ID: 7941190
[TBL] [Abstract][Full Text] [Related]
7. Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder.
Rosen EM; Joseph A; Jin L; Yao Y; Chau MH; Fuchs A; Gomella L; Hastings H; Goldberg ID; Weiss GH
J Urol; 1997 Jan; 157(1):72-8. PubMed ID: 8976219
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive molecular detection of bladder cancer recurrence.
Amira N; Mourah S; Rozet F; Teillac P; Fiet J; Aubin P; Cortesse A; Desgrandchamps F; Le Duc A; Cussenot O; Soliman H
Int J Cancer; 2002 Sep; 101(3):293-7. PubMed ID: 12209982
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
[TBL] [Abstract][Full Text] [Related]
10. Autocrine motility factor receptor as a possible urine marker for transitional cell carcinoma of the bladder.
Korman HJ; Peabody JO; Cerny JC; Farah RN; Yao J; Raz A
J Urol; 1996 Jan; 155(1):347-9. PubMed ID: 7490884
[TBL] [Abstract][Full Text] [Related]
11. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
[TBL] [Abstract][Full Text] [Related]
12. Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer.
Kelloniemi E; Rintala E; Finne P; Stenman UH;
Urology; 2003 Aug; 62(2):249-53. PubMed ID: 12893328
[TBL] [Abstract][Full Text] [Related]
13. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma.
Klein A; Zemer R; Buchumensky V; Klaper R; Nissenkorn I
Cancer; 1998 Jan; 82(2):349-54. PubMed ID: 9445193
[TBL] [Abstract][Full Text] [Related]
14. Urine markers for bladder cancer surveillance: a systematic review.
Ratliff TL
J Urol; 2005 Nov; 174(5):2065-6. PubMed ID: 16217395
[No Abstract] [Full Text] [Related]
15. Detection and quantification of soluble intercellular adhesion molecule-1 (sICAM-1) in the serum and urine of patients with bladder cancer.
Shi BB; Goya N; Okuda H; Ryoji O; Nakazawa H; Toma H
Int J Urol; 1998 Jul; 5(4):324-8. PubMed ID: 9712439
[TBL] [Abstract][Full Text] [Related]
16. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
17. Cellular fibronectin in patients with transitional cell carcinoma of the bladder.
Hegele A; Heidenreich A; Varga Z; von Knobloch R; Olbert P; Kropf J; Hofmann R
Urol Res; 2003 Feb; 30(6):363-6. PubMed ID: 12599015
[TBL] [Abstract][Full Text] [Related]
18. Urine and serum cathepsin B concentrations in the transitional cell carcinoma of the bladder.
Kotaska K; Dusek P; Prusa R; Vesely S; Babjuk M
J Clin Lab Anal; 2012 Feb; 26(2):61-5. PubMed ID: 22467319
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
20. Serum and urinary levels of beta human chorionic gonadotrophin in patients with transitional cell carcinoma.
McLoughlin J; Pepera T; Bridger J; Williams G
Br J Cancer; 1991 May; 63(5):822-4. PubMed ID: 1710137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
